Ird Luxturna denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for ird luxturna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Luxturna for IRD as "Experimental" — and Why That Denial Is Challengeable

An "experimental or investigational" denial for Luxturna (voretigene neparvovec) in inherited retinal dystrophy caused by biallelic RPE65 mutations is directly contradicted by the drug's regulatory status: Luxturna holds full FDA approval specifically for this indication. FDA approval is the standard benchmark used by most insurers — including Cigna — to distinguish established from experimental treatment.

This type of denial most commonly arises because Cigna's internal coverage policy has not been updated to reflect FDA approval, because the drug was submitted under an incorrect code, or because Cigna is applying an outdated or overly restrictive definition of "experimental" that contradicts regulatory reality.

## Your Federal Appeal Rights

• ERISA §503: Full-and-fair internal review entitles you to a peer-to-peer review by a clinician with relevant expertise (ideally a retinal specialist or ophthalmologist with gene therapy experience). Request this explicitly.
• ACA §2719 external review: An independent external reviewer has the authority to overturn a denial based on incorrect classification. The external-review window is generally four months from the denial notice. Given the irreversible, progressive nature of RPE65-associated retinal dystrophy, apply for expedited external review — most programs resolve expedited cases within 72 hours.
• State insurance department: Denying an FDA-approved therapy as "experimental" may be an improper claims practice in your state — file a complaint in parallel with your appeal.

## Concrete Appeal Steps

1. Download the official FDA approval letter and prescribing label for Luxturna from FDA.gov — attach them as the primary exhibit to your appeal. 2. Request Cigna's written coverage policy (medical policy or coverage determination) for Luxturna or voretigene neparvovec — if it predates the FDA approval date, make that discrepancy explicit. 3. Ask for a peer-to-peer call between your retinal specialist and Cigna's medical reviewer. 4. Have your prescriber prepare a letter confirming the FDA-approved indication and your patient's eligibility for it. 5. If the internal appeal is denied, file for expedited external review immediately.

## Documentation to Gather

• FDA prescribing label and approval date: The foundational rebuttal to any "experimental" characterization.
• Genetic testing results: Molecular confirmation of biallelic RPE65 mutations, demonstrating that your case falls precisely within the FDA-approved indication.
• Ophthalmology and retinal specialist records: ERG results, visual field testing, OCR imaging, and specialist notes documenting the diagnosis, current visual function, and rate of progression.
• Prescriber letter: Explicitly referencing FDA approval, your confirmed mutation, and the clinical rationale for treatment.
• Cigna coverage policy version date: If the policy predates FDA approval, note that discrepancy directly in your appeal letter.

## Criteria-Mapping Structure

| Cigna's Experimental Criterion | Rebuttal Evidence | |---|---| | Drug lacks FDA approval | FDA approval letter (attach) | | Not supported by clinical evidence | FDA label clinical data section; professional ophthalmology society guidelines | | [Any other criterion Cigna specifies] | [Exact documentation] |